Wednesday, October 17, 2018 Print page
Centre of Inflammation and Metabolism (CIM)


To read the abstract, please click on the title of the publication of interest. If you want to access the publication on PubMed, please click on the PubMed ID.
To find specific publications, please use the sort and search functions. Please enter one word only as search term.

Click here to see all publications

95IL-6, but not TNF-alpha, increases plasma YKL-40 in human subjects.
Nielsen AR; Plomgaard P; Krabbe KS; Johansen JS; Pedersen BK
Cytokine 2011; 55(1): 152-5
PubMed ID: 21478032

Plasma levels of YKL-40 are elevated in patients with systemic infection, inflammatory disorders and cancer. Both monocytes/macrophages, neutrophils, and cancer cells have the capacity to produce YKL-40, but the regulation during the inflammatory response is unknown. To study the possible role of interleukin-6 (IL-6) and tumor necrosis factor (TNF)-alpha in the regulation of YKL-40 plasma levels, we included healthy men, who received either recombinant human (rh)IL-6 (n=6), rhTNF-alpha (n=8) or vehicle (n=7) for 3h. The plasma levels of IL-6 and TNF-alpha reached approximately 150 and approximately 18 pg/ml, respectively, during the infusions. Following the IL-6 infusion, the plasma level of YKL-40 increased from approximately 30 to approximately 57 ng/ml (p<0.05) at 24h, and returned to normal values after 48 h. The plasma level of YKL-40 did not change during TNF-alpha infusion or infusion of vehicle. These data demonstrate that IL-6, but not TNF-alpha, has a key-role in the regulation of plasma YKL-40 levels during inflammation. Copyright (c) 2011 Elsevier Ltd. All rights reserved.

© 2018 Centre of Inflammation and Metabolism